1
James E Woiszwillo, Larry R Brown, Terrence L Scott, Jie Di, Judith Sudhalter, Charles D Blizzard: Macromolecular microparticles and methods of production and use. Epic Therapeutics, Jones & Askew, July 18, 2000: US06090925 (165 worldwide citation)

Microparticles formed by mixing a macromolecule with a polymer at a pH near the isoelectric point of the macromolecule and incubating the mixture in the presence of an energy source for a predetermined length of time. The microparticles are composed of homogeneously distributed, intertwined macromol ...


2
James E Woiszwillo, Larry R Brown, Terrence L Scott, Jie Di, Judith Sudhalter, Charles D Blizzard, Frank J Riske: Macromolecular microparticles and methods of production and use. Epic Therapeutics, Jones & Askew, November 9, 1999: US05981719 (145 worldwide citation)

Microparticles formed by mixing a macromolecule with a polymer at a pH near the isoelectric point of the macromolecule and incubating the mixture in the presence of an energy source for a predetermined length of time. The microparticles are composed of homogeneously distributed, intertwined macromol ...


3
James E Woiszwillo, Larry R Brown, Terrence L Scott, Jie Di, Judith Sudhalter, Charles D Blizzard, Frank J Riske: Macromolecular microparticles and methods of production and use. Epic Therapeutics, Wolf Greenfield & Sacks P C, July 31, 2001: US06268053 (114 worldwide citation)

Methods relating to the field of biochemistry and more specifically relating to microparticles for use in diagnostics, therapeutics, and research are provided.


4
Terrence L Scott, Larry R Brown, Frank J Riske, Charles D Blizzard, Julia Rashba Step: Sustained release microspheres. Epic Therapeutics, Wolf Greenfield & Sacks P C, October 1, 2002: US06458387 (90 worldwide citation)

Methods for forming sustained release microspheres and the products produced thereby are provided. The microspheres have a smooth surface that includes a plurality of channel openings that are less than 1000 angstroms in diameter.


5
Larry Brown, John K McGeehan, Julia Rashba Step, Terrence L Scott: Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation. Baxter International, Baxter Healthcare, Marshall Gerstein & Borun, December 13, 2011: US08075919 (12 worldwide citation)

The present invention is related to a method for preparing small spherical particles of an active agent by providing a solution in a single liquid phase. The single liquid phase comprises an active agent, a phase separation enhancing agent, and a first solvent. A phase change is induced at a control ...


6
James E Woiszwillo, Larry R Brown, Terrence L Scott, Jie Di, Judith Sudhalter, Charles D Blizzard: Macromolecular microparticles and methods of production and use. Epic Therapeutics, Jones Askew, December 15, 1998: US05849884 (7 worldwide citation)

Microparticles formed by mixing a macromolecule with a polymer at a pH near the isoelectric point of the macromolecule and incubating the mixture in the presence of an energy source for a predetermined length of time. The microparticles are composed of homogeneously distributed, intertwined macromol ...


7
Larry R Brown, Vered Bisker Leib, Terrence L Scott, Debra Lafreniere, Jennifer Machen, Nick Giannoukakls: Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes. Baxter International, Baxter Healthcare, University of Pittsburgh of the Commonwealth System of Higher Education, Marshall Gerstein & Borun, February 8, 2011: US07884085 (1 worldwide citation)

AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes ...


8
Larry R Brown, Vered Bisker Leib, Terrence L Scott, Debra Lafreniere, Jennifer Machen, Nick Giannoukakis: Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes. BAXTER INTERNATIONAL, BAXTER HEALTHCARE, UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Marshall Gerstein & Borun, August 25, 2015: US09115357

AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes ...


9
Larry R Brown, Terrence L Scott, Debra Lafreniere, Vered Bisker Leib: Nucleic acid microspheres, production and delivery thereof. Baxter Healthcare, Baxter International, Marshall Gerstein & Borun, October 19, 2010: US07815941

Nucleic acids are prepared by dissolving compounds containg them in a suitable solvent or solvent system and forming microspheres from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nucleic acids is useful, such as in treatm ...


10
Julia Rashba Step, Terrence L Scott, Ramin Darvi, Yuri Lvov, Tatsiana Shutava: Surface-modified microparticles and methods of forming and using the same. Baxter Healthcare Corporation, November 23, 2006: US20060260777-A1

Surface-modified microparticles and methods of making and using such particles are disclosed. The surface modified microparticles include a preformed or core microparticle that contains at least one active agent. The outer surface of the preformed or core microparticle carries a net surface charge. ...